From Wikipedia, the free encyclopedia
Experimental drug
ZSP1601 is an experimental pan-
phosphodiesterase inhibitor developed by Guangdong Raynovent Biotech for
nonalcoholic steatohepatitis.
[1]
[2]
References
-
^ Zhu, Xiaoxue; Wu, Min; Wang, Hong; Li, Haijun; Lin, Junjie; Peng, Yun; Hu, Yue; Li, Cuiyun; Ding, Yanhua (4 May 2021). "Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study". Expert Opinion on Investigational Drugs. 30 (5): 579–589.
doi:
10.1080/13543784.2021.1900822.
PMID
33682556.
S2CID
232140574.
-
^ Hu, Yue; Li, Haijun; Zhang, Hong; Chen, Xiaoxin; Chen, Jinjun; Xu, Zhongyuan; You, Hong; Dong, Ruihua; Peng, Yun; Li, Jing; Li, Xiaojiao; Wu, Dandan; Zhang, Lei; Cao, Di; Jin, He; Qiu, Dongdong; Yang, Aruhan; Lou, Jinfeng; Zhu, Xiaoxue; Niu, Junqi; Ding, Yanhua (12 October 2023).
"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial". Nature Communications. 14 (1): 6409.
Bibcode:
2023NatCo..14.6409H.
doi:
10.1038/s41467-023-42162-0.
ISSN
2041-1723.
PMC
10570369.
PMID
37828034.